vs
Esperion Therapeutics, Inc.（ESPR）与JBG SMITH Properties（JBGS）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是JBG SMITH Properties的1.3倍（$168.4M vs $127.6M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -2.5%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -6.3%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
JBG SMITH Properties是一家总部位于马里兰州贝塞斯达的上市房地产投资信托公司，专注于持有并运营房地产资产，是美国商业地产领域的专业运营机构，面向市场提供多元化的不动产投资与管理服务。
ESPR vs JBGS — 直观对比
营收规模更大
ESPR
是对方的1.3倍
$127.6M
营收增速更快
ESPR
高出146.2%
-2.5%
两年增速更快
ESPR
近两年复合增速
-6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $127.6M |
| 净利润 | — | $-45.5M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | -47.5% |
| 净利率 | — | -35.7% |
| 营收同比 | 143.7% | -2.5% |
| 净利润同比 | — | 24.0% |
| 每股收益（稀释后） | $0.32 | $-0.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRJBGS
| Q4 25 | $168.4M | $127.6M | ||
| Q3 25 | $87.3M | $123.9M | ||
| Q2 25 | $82.4M | $126.5M | ||
| Q1 25 | $65.0M | $120.7M | ||
| Q4 24 | $69.1M | $130.8M | ||
| Q3 24 | $51.6M | $136.0M | ||
| Q2 24 | $73.8M | $135.3M | ||
| Q1 24 | $137.7M | $145.2M |
净利润ESPRJBGS
| Q4 25 | — | $-45.5M | ||
| Q3 25 | $-31.3M | $-28.6M | ||
| Q2 25 | $-12.7M | $-19.2M | ||
| Q1 25 | $-40.5M | $-45.7M | ||
| Q4 24 | — | $-59.9M | ||
| Q3 24 | $-29.5M | $-27.0M | ||
| Q2 24 | $-61.9M | $-24.4M | ||
| Q1 24 | $61.0M | $-32.3M |
营业利润率ESPRJBGS
| Q4 25 | 50.6% | -47.5% | ||
| Q3 25 | -11.4% | -27.5% | ||
| Q2 25 | 8.6% | -18.4% | ||
| Q1 25 | -34.0% | -44.7% | ||
| Q4 24 | -6.4% | -53.6% | ||
| Q3 24 | -31.0% | -22.4% | ||
| Q2 24 | 3.5% | -24.3% | ||
| Q1 24 | 52.5% | -30.1% |
净利率ESPRJBGS
| Q4 25 | — | -35.7% | ||
| Q3 25 | -35.9% | -23.1% | ||
| Q2 25 | -15.4% | -15.2% | ||
| Q1 25 | -62.2% | -37.9% | ||
| Q4 24 | — | -45.8% | ||
| Q3 24 | -57.2% | -19.8% | ||
| Q2 24 | -83.9% | -18.0% | ||
| Q1 24 | 44.3% | -22.2% |
每股收益（稀释后）ESPRJBGS
| Q4 25 | $0.32 | $-0.76 | ||
| Q3 25 | $-0.16 | $-0.48 | ||
| Q2 25 | $-0.06 | $-0.29 | ||
| Q1 25 | $-0.21 | $-0.56 | ||
| Q4 24 | $-0.14 | $-0.70 | ||
| Q3 24 | $-0.15 | $-0.32 | ||
| Q2 24 | $-0.33 | $-0.27 | ||
| Q1 24 | $0.34 | $-0.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $75.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $1.2B |
| 总资产 | $465.9M | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRJBGS
| Q4 25 | $167.9M | $75.3M | ||
| Q3 25 | $92.4M | $64.4M | ||
| Q2 25 | $86.1M | $61.4M | ||
| Q1 25 | $114.6M | $81.3M | ||
| Q4 24 | $144.8M | $145.8M | ||
| Q3 24 | $144.7M | $137.0M | ||
| Q2 24 | $189.3M | $163.5M | ||
| Q1 24 | $226.6M | $220.5M |
股东权益ESPRJBGS
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.2B | ||
| Q2 25 | $-433.5M | $1.3B | ||
| Q1 25 | $-426.2M | $1.6B | ||
| Q4 24 | $-388.7M | $1.8B | ||
| Q3 24 | $-370.2M | $1.9B | ||
| Q2 24 | $-344.2M | $2.0B | ||
| Q1 24 | $-294.3M | $2.1B |
总资产ESPRJBGS
| Q4 25 | $465.9M | $4.4B | ||
| Q3 25 | $364.0M | $4.4B | ||
| Q2 25 | $347.1M | $4.5B | ||
| Q1 25 | $324.0M | $4.7B | ||
| Q4 24 | $343.8M | $5.0B | ||
| Q3 24 | $314.1M | $5.2B | ||
| Q2 24 | $352.3M | $5.3B | ||
| Q1 24 | $373.1M | $5.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $73.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRJBGS
| Q4 25 | $45.2M | $73.3M | ||
| Q3 25 | $-4.3M | $8.9M | ||
| Q2 25 | $-31.4M | $18.8M | ||
| Q1 25 | $-22.6M | $12.9M | ||
| Q4 24 | $-35.0M | $129.4M | ||
| Q3 24 | $-35.3M | $26.4M | ||
| Q2 24 | $-7.2M | $23.8M | ||
| Q1 24 | $53.8M | $37.0M |
自由现金流ESPRJBGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
自由现金流率ESPRJBGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
资本支出强度ESPRJBGS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率ESPRJBGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
JBGS
暂无分部数据
